RESUMO
In this multicenter study, we aimed to evaluate the performance of MALDI Biotyper and VITEK MS, for identification of Prevotella species. Three hundred and fourteen clinical isolates, collected in eight European countries between January 2014 and April 2016, were identified at the collecting sites by MALDI Biotyper (versions 3.0 and 3.1) and then reidentified by VITEK MS (version 3.0) in the central laboratory. 16S rRNA gene sequencing was used as a standard method. According to sequence analysis, the 314 Prevotella strains belonged to 19 species. MALDI Biotyper correctly identified 281 (89.5%) isolates to the species level and 33 (10.5%) only at the genus level. VITEK MS correctly identified 253 (80.6%) isolates at the species level and 276 (87.9%) isolates at the genus level. Thirty-three isolates belonging to P. bergensis, P. conceptionensis, P. corporis, P. histicola, and P. nanciensis, unavailable in the VITEK MS 3.0 database, were resulted in genus level or no identification. Six Prevotella strains, belonged to P. veroralis, P. timonensis, and P. conceptionensis not represented in the MALDI Biotyper system database, were misidentified at the genus level. In conclusion, both VITEK MS and MALDI Biotyper provided reliable and rapid identification. However, the permanent extension of the databases is needed.
Assuntos
Técnicas de Tipagem Bacteriana/métodos , Prevotella/química , Prevotella/classificação , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz/métodos , Infecções por Bacteroidaceae/microbiologia , Europa (Continente) , Humanos , Análise de Sequência de DNARESUMO
HPV infections are common and the presence of the same high-risk type in cervical specimens can be due to reinfection or persistence. Persistent infection is the most important predictor for development of cervical carcinoma. The aim of this study was to validate PCR-RFLP with two sets of primers: MY09/MY11 that amplify a fragment of L1 and P1/P2 that amplify a fragment of E1 ORF. PCR product of MY09/MY11 was digested with a set of 6 restriction enzymes (RE) and PCR product of P1/P2 with a set of 12 RE. Cervical samples from 110 women patients of the University Gynecologic Clinic CHC Zagreb were analyzed. There were 98 (89.1%) PCR positive samples detected with P1/P2 primers, and 94 (85.5%) PCR positive samples detected with MY09/MY11 primers. Seven HPV types were detected with P1/P2-RFLP technique and 17 with MY09/MY11-RFLP PCR positive samples amplified with both primer pairs agreed with each other in 82 samples; 16 samples were only positive with P1/P2 and 12 samples were only positive by MY09/MY11. HPV 16 was detected in 39 samples with MY09/11-RFLP, out of these two variants (two different patterns) were found with P1/P2 using Dde I, Hae III and Eco I. HPV 6 was detected in 9 samples with MY09/11-RFLP, out of these two variants were found with P1/P2 using HinfI. Combining these two PCR-RFLP methods subtypes of HPV 16 and HPV 6 were detected.
Assuntos
Colo do Útero/virologia , Papillomavirus Humano 16/classificação , Papillomavirus Humano 6/classificação , Polimorfismo de Fragmento de Restrição , Feminino , Papillomavirus Humano 16/genética , Papillomavirus Humano 6/genética , HumanosRESUMO
Summary. The development of the Guidelines for perioperative prophylactic use of antimicrobial agents (further on Guidelines) was initiated by the Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) of the Croatian Ministry of Health and Social Welfare in accordance with the principles of AGREE (Appraisal of Guidelines for Research and Evaluation) methodology which means that the guidelines are the result of a consensus between all involved professional societies. Guidelines were composed in order to improve antibiotic use in surgical professions. Data obtained from observational studies have shown that the use of antimicrobials in surgical professions is unsatisfactory, and since around 50% of all prescribed drugs in surgical professions refer to perioperative prophylaxis, such guidelines could significantly improve current negative trend and reduce the occurrence of infections in surgical patients as well as slow down the selection of resistant bacteria. In the introductory part of the guidelines, principles of perioperative prophylaxis are presented. The advantages and risks of prophylaxis are listed as well as factors that determine prophylaxis effectiveness. For easier orientation, surgical professions have been divided into basic surgical fields. In each field, the specificity of the field has been described followed by uniform structured tables and with every listed surgical procedure there is the most probable cause of infection, the drug of choice for prophylaxis, alternative drug, remark for particular surgical procedure and finally the grade of recommendation. The Guidelines do not cover perioperative prophylaxis in immunocompromised patients nor perioperative prophylaxis in children. The Guidelines do not cover all possible surgical interventions, but can be used as a basis for most surgical procedures performed in our hospitals. At the very end of these Guidelines, a comprehensive list of references enables all those interested to find further information and details about this topic. The revision of the Guidelines is planned in three years' time.
Assuntos
Antibioticoprofilaxia , Infecção da Ferida Cirúrgica/prevenção & controle , Croácia , Humanos , Assistência PerioperatóriaRESUMO
AIM: To determine the effect of aminoglycoside cycling in six tertiary intensive care units (ICU) on the rates of sepsis, aminoglycoside resistance patterns, antibiotic consumption, and costs. METHODS: This was a prospective longitudinal interventional study that measured the effect of change from first-line gentamicin usage (February 2002-February 2003) to amikacin usage (February 2003-February 2004) on the aminoglycoside resistance patterns, number of patients with gram-negative bacteremia, consumption of antibiotics, and the cost of antimicrobial drugs in 6 tertiary care ICUs in Zagreb, Croatia. RESULTS: The change from first-line gentamicin to amikacin usage led to a decrease in the overall gentamicin resistance of gram-negative bacteria (GNB) from 42% to 26% (P<0.001; z-test of proportions) and netilmicin resistance from 33% to 20% (P<0.001), but amikacin resistance did not change significantly (P=0.462), except for Acinetobacter baumanni (P=0.014). Sepsis rate in ICUs was reduced from 3.6% to 2.2% (P<0.001; chi(2) test), with a decline in the number of nosocomial bloodstream infections from 55/100 patient-days to 26/100 patient-days (P=0.001, chi(2) test). Furthermore, amikacin use led to a 16% decrease in the overall antibiotic consumption and 0.1 euro/patient/d cost reduction. CONCLUSION: Exclusive use of amikacin significantly reduced the resistance of GNB isolates to gentamicin and netilmicin, the number of GNB nosocomial bacteremias, and the cost of total antibiotic usage in ICUs.
Assuntos
Amicacina/uso terapêutico , Aminoglicosídeos/uso terapêutico , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Gentamicinas/uso terapêutico , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Unidades de Terapia Intensiva/estatística & dados numéricos , Netilmicina/uso terapêutico , Sepse/tratamento farmacológico , Amicacina/administração & dosagem , Aminoglicosídeos/administração & dosagem , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Análise Custo-Benefício , Croácia , Gentamicinas/administração & dosagem , Infecções por Bactérias Gram-Negativas/economia , Humanos , Estudos Longitudinais , Netilmicina/administração & dosagem , Estudos Prospectivos , Sepse/economiaRESUMO
OBJECTIVE: To detect Mycoplasma genitalium in urine samples of infertile men and men without any signs of infection in order to investigate whether M. genitalium and other genital mycoplasmas (Mycoplasma hominis and Ureaplasma spp) are found more often in urine samples of infertile men than in asymptomatic controls and to determine resistance to macrolides. METHODS: The study included first void urine samples taken from 145 infertile men and 49 men with no symptoms of urethritis. M. genitalium, Chlamydia trachomatis and Neisseria gonorrhoeae were detected by commercial PCR. Trichomonas vaginalis was detected by microscopy and culture. M. hominis and Ureaplasma spp were detected by culture. M. genitalium was detected by in-house conventional and real-time PCR. RESULTS: Two M. genitalium positive samples were found among samples obtained from infertile men. All asymptomatic men were M. genitalium negative. Macrolide resistance was not found in either of the two positive samples. CONCLUSIONS: In comparison with reported data, an unusually low prevalence of M. genitalium was found in infertile men. The reasons for this unexpected result are not known; possibly, local demographic and social characteristics of the population influenced the result. Further studies to investigate M. genitalium in infertile and other groups of patients are needed.
Assuntos
Chlamydia trachomatis/isolamento & purificação , Doenças dos Genitais Masculinos/microbiologia , Infertilidade Masculina/microbiologia , Mycoplasma genitalium/isolamento & purificação , Mycoplasma hominis/isolamento & purificação , Neisseria gonorrhoeae/isolamento & purificação , Adulto , Croácia/epidemiologia , Estudos Transversais , DNA Bacteriano/efeitos dos fármacos , Resistência Microbiana a Medicamentos , Doenças dos Genitais Masculinos/epidemiologia , Voluntários Saudáveis , Humanos , Infertilidade Masculina/urina , Masculino , Prevalência , Reação em Cadeia da Polimerase em Tempo Real , Sêmen/microbiologiaRESUMO
Mycoplasma genitalium is considered the smallest self-replicating cell. It was first isolated in 1981, from 2 of 13 men with urethritis. Mycoplasma genitalium causes urethritis, cervicitis and pelvic inflammatory disease. Because of difficulties in cultivation, the diagnosis is based exclusively on PCR methodology. The recommended therapy for Mycoplasma genitalium infections is azithromycin or doxycycline. Development of macrolide resistance was shown to correlate with treatment failure.
Assuntos
Infecções por Mycoplasma/diagnóstico , Mycoplasma genitalium , Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Doxiciclina/uso terapêutico , Feminino , Humanos , Masculino , Infecções por Mycoplasma/tratamento farmacológico , Uretrite/microbiologia , Cervicite Uterina/microbiologiaRESUMO
AIM: The aim of this study was to determine a percentage of high risk genotypes which are included in the current vaccines in women with different cytology and on the basis of obtained results to evaluate the protective activity of the current vaccines. METHODS: Endocervical swabs were taken from 70 women with different cervical cytology (25 women with CIN 1, 25 women with CIN 2/3 and 20 women with negative cytology). The samples were tested by PCR method using MY09/MY11 primers to determinate the HPV status, especially the percentage of high risk genotypes which are not included in the current vaccines. Genotyping was done by RFLP method. RESULTS: In as much as 38.8% of all samples high risk genotypes (hrHPV), not included in the current vaccine, were detected; in a group of women with normal cytology hrHPV genotypes were found in 29.9% samples. HrHPV were found in 47%, and 64% of samples taken from women with normal cytology and CIN 1, respectively, while in women with CIN 2/3 hrHPV were found in 94%. CONCLUSION: These results indicate that in more than in one third of tested women the current available vaccines would be of minimal protective activity, but further studies which should include more women are needed.